Home Tags Anti-FOLR1

Tag: anti-FOLR1

The AACR Annual Meeting in better times - before COVID19: the AACR annual meeting opening plenary session in 2018 at the McCormick Convention Center in Chicago, Illinois with the 2019 president-elect Elaine Mardis, Ph.D, who served as program committee chair for this 2018 meeting, addressed attendees. Photo Courtesy © AACR/Todd Buchanan.

AACR 2020: Phase I Clinical Trial with STRO-002 Shows Encouraging...

Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going Phase I dose-escalation phase clinical...
AACR Annual Meeting 2014

Refined Dosing Strategy for IMGN853 Achieves Objective

Data presented at the annual meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA. shows clinical activity with IMGN853 (ImmunoGen), an antibody drug conjugate or ADC currently in Phase I clinical testing for the treatment of folate receptor α (FRα)-positive cancers, including ovarian, endometrial, lung and other cancers, starting at doses of 3.3 mg/kg.